Bristol Myers Squibb had its Relative Strength (RS) Rating upgraded from 63 to 79 Tuesday — a welcome improvement, but still shy of the 80 or better score you look for.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Bristol Myers Squibb can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
While the stock is not near an ideal buy point right now, see if it goes on to form and break out from a proper consolidation.
Bristol Myers Squibb reported -10% EPS growth in its most recent report, while sales growth came in at 8%.
Bristol Myers Squibb holds the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health is the top-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
